摘要
目的观察肾康灵干预小儿频复发性肾病(FRNS)治疗前后脂蛋白a(Lpa)的变化,探讨小儿FRNS的发病机制及肾康灵冲剂干预治疗的作用机制。方法将60例FRNS患儿随机分为治疗组和对照组各30例,对照组予以强的松加降脂、抗血小板聚集药物治疗,治疗组予以肾康灵冲剂合强的松治疗。观察2组治疗前及尿蛋白转阴2周后的血脂蛋白a(Lpa)和胆固醇(TC)、甘油三酯(TG)等变化。应用SPSS13.0统计软件对数据进行统计学处理。结果治疗后2组Lpa、TC比较明显低于治疗前(P<0.01),但TG与治疗前比较无显著差异(P>0.05);治疗组治疗后的Lpa、TC、TG与对照组比较无显著差异(P>0.05)。结论①FRNS患儿血浆Lpa水平明显增高,Lpa可作为FRNS患儿脂质代谢紊乱及高凝状态的检测指标。②益肾活血中药肾康灵具有明显的降脂作用,能有效拮抗FRNS所引起的血浆胆固醇水平升高,改善高脂血症及高凝状态。
Objective To observe the change of lipoprotein a（LPa） before and after the treatment in children with frequent relapse nephrotic syndrome（FRNS） treated by Shenkangling,and discuss the pathogenesis of FRNS and the mechanism of Shenkangling from the view of lipid metabolism.Methods 60 chil dren with FRNS were randomly assigned to two groups,the treatment group（n=30） were taken Shenkangling and prednisone,and the control group（n=30） received prednisone combined with drugs of lipid-lowering and antiplatelet aggregation.The changes of LPa,total cholesterol（TC） and triglyceride（TG） were observed before the teatment and 2 weeks after urinary protein became negative.Results There was not significant difference in levels of LPa,TC and TG between two groups before the treatment（P0.05）.After the treatment,the levels of LPa and TC were decreased in both two groups,and the differences before and after the treatment were significant（P0.01）.There was not significant difference in levels of LPa,TC and TG between two groups after the treatment（P0.05）.Conclusion The plasma LPa level in FRNS children was obviously higher than that in normal children,and LPa can be used as the detection index of lipid metabolism disorder and hypercoagulabale state in FRNS children.Shenkanglingthe has obvious lipid-lowering effect,and could effectively antagonize the increasing of plasma cholesterol level induced by FRNS and improve hyperlipidemia and hypercoagulable state.
出处
《福建中医药大学学报》
2010年第4期4-6,共3页
Journal of Fujian College of Traditional Chinese Medicine
关键词
小儿
频复发性肾病
益肾活血法
肾康灵
脂蛋白A
children
frequent relapse nephrotic syndrome
tonifying kidney and activating blood
Shenkangling
lipoprotein a
